WATERTOWN, Mass.--(BUSINESS WIRE)--Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) today announced the upcoming presentation of six scientific posters at the 24th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) taking place May 10-13, 2014 in Barcelona, Spain.
“We are excited to be presenting data on multiple antibiotic candidates at ECCMID this year,” said Guy Macdonald, President and CEO of Tetraphase. “Notably, the presentations cover new safety data on our Phase 3 antibiotic candidate eravacycline; preclinical studies demonstrating in vivo efficacy of eravacycline and our preclinical candidate TP-271 against certain biothreat pathogens; and additional preclinical data from the newest drug candidates discovered through our in-house antibiotic chemistry platform. We are particularly pleased with the activity of these early stage compounds against some of the most difficult-to-treat Gram-negative pathogens, including species of Carbapenem-resistant Enterobacteriaceae (CRE), bacteria specifically identified by the CDC and the World Health Organization as urgent threats to public health.”
Poster #P0301 entitled, “Eravacycline Does Not Prolong Corrected QT Intervals in a Thorough QT Study Conducted in Healthy Subjects,” will be presented during the session on New Therapeutic Alternatives from 3:30 PM to 4:30 PM CEST on Saturday, May 10th.
Poster #P0109, entitled “Eravacycline Protects in a Bacillus anthracis-Infected New Zealand White Rabbit Treatment Model,” will be presented during the session on Animal Models from 3:30 PM to 4:30 PM CEST on Saturday, May 10th.
Poster #P1228, entitled “Multi-Locus Sequence Typing of Escherichia coli Isolates from a Phase 2 Complicated Intra-Abdominal Trial for Eravacycline,” will be presented during the session on Global Epidemiology and Molecular Typing from 1:30 PM to 2:30 PM CEST on Monday, May 12th.
Eravacycline is a fully synthetic tetracycline derivative being developed by Tetraphase as an intravenous and oral antibiotic for the treatment of serious, resistant Gram-negative infections.
Poster #P0111, entitled “TP-271, a Novel Fluorocycline, is Efficacious in a Treatment Model of Aerosolized Francisella tularensis Infection in BALB/c Mice,” will be presented during the session on Animal Models from 3:30 PM to 4:30 PM CEST on Saturday, May 10th.
TP-271, a novel tetracycline antibiotic currently in preclinical development, is being developed to combat respiratory disease caused by bacterial biothreats and antibiotic-resistant pathogens.
2nd Generation Gram-negative Program Presentations
Poster #P0299, entitled “In Vitro Potency of Novel, Fully Synthetic Tetracyclines against MDR Gram-negative Pathogens Including Carbapenem-resistant Enterobacteriaceae,” will be presented during the session on New Therapeutic Alternatives from 3:30 PM to 4:30 PM CEST on Saturday, May 10th.
Poster #P0300, entitled “In Vivo Efficacy of Novel, Fully Synthetic Tetracyclines in a Murine Lung Infection Model Challenged with KPC-producing Klebsiella pneumoniae,” will be presented during the session on New Therapeutic Alternatives from 3:30 PM to 4:30 PM CEST on Saturday, May 10th.
Tetraphase’s 2nd-Generation Gram-negative Program is focused on the discovery of tetracycline-derived compounds active against the most urgent multidrug-resistant Gram-negative bacterial health threats identified by the CDC in its September 2013 report.
Notes on Studies
The studies supporting posters P0109 and P0301 were funded in whole or in part with Federal Funds from the Biomedical Advanced Research and Development Authority (BARDA), Office of the Assistant Secretary for Preparedness and Response, Office of the Secretary, Department of Health and Human Services, under Contract No HHSO100201200002C.
The studies supporting poster P0111 were funded by the National Institute of Allergy and Infectious Diseases (NIAID) Participation Grant #: 1R01AI093484-01 and NIAID Contract #: HHSN272201100028C.
About Tetraphase Pharmaceuticals, Inc.
Tetraphase is a clinical-stage biopharmaceutical company using its proprietary chemistry technology to create novel antibiotics for serious and life-threatening multidrug-resistant (MDR) bacterial infections, including those caused by many of the MDR Gram-negative bacteria highlighted as urgent public health threats by the Centers for Disease Control and Prevention (CDC). Tetraphase's lead product candidate, eravacycline, is being developed as a broad-spectrum intravenous and oral antibiotic in the IGNITE program (Investigating Gram-negative Infections Treated with Eravacycline). Under this program, two Phase 3 clinical trials are ongoing: IGNITE 1 for the indication of complicated intra-abdominal infections (cIAI) and IGNITE 2 for complicated urinary tract infections (cUTI). Tetraphase has created more than 3,000 novel tetracycline analogs using its technology platform; in addition to eravacycline, Tetraphase has generated multiple preclinical antibiotic candidates that are currently being evaluated for clinical suitability. Please visit www.tphase.com for more company information.
Any statements in this press release about our future expectations, plans and prospects, including statements regarding our strategy, future operations, prospects, plans and objectives, and other statements containing the words “anticipates,” “believes,” “expects,” “plans,” “will” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: whether results obtained in preclinical studies and early clinical trials will be indicative of results obtained in future clinical trials; whether our drug candidates will advance through the clinical trial process on a timely basis or at all; and other factors discussed in the “Risk Factors” section of our most recent Annual Report on Form 10-K, filed with the Securities and Exchange Commission on March 6, 2014. In addition, the forward-looking statements included in this press release represent our views as of May 9, 2014. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we specifically disclaim any obligation to do so.